Rabeprazole 20 mg for erosive esophagitis-associated symptoms in a large, community-based study: additional results

Dig Dis Sci. 2010 Feb;55(2):338-45. doi: 10.1007/s10620-009-0864-7. Epub 2009 Jun 26.

Abstract

Purpose: To provide additional efficacy data in patients treated with rabeprazole through week 4, and to validate sustained relief of gastroesophageal reflux disease symptoms through week 8 as well as to further analyze rabeprazole safety in patients with wide-ranging demographic and clinical characteristics.

Results: Patients in this study (N = 2,449) demonstrated significant overall improvement versus baseline (P < 0.001). Substantial symptom relief was seen throughout 8 weeks of treatment. By week 4, complete relief of daytime and nighttime heartburn, belching, regurgitation, and dysphagia was observed in 87.5, 90.7, 50.7, 77.6, and 75.1% of patients, respectively. Improvements were seen in rabeprazole-treated patients (<65 or >or=65 years) with a range of baseline symptom severities and across different racial groups. Rabeprazole was well tolerated.

Conclusions: In patients with endoscopy-confirmed erosive esophagitis treated with once-daily rabeprazole 20 mg, prompt and continuing improvements were seen in daytime and nighttime heartburn, belching, regurgitation, and dysphagia.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage*
  • Aged
  • Dose-Response Relationship, Drug
  • Endoscopy, Gastrointestinal
  • Enzyme Inhibitors / administration & dosage*
  • Esophagitis, Peptic / complications
  • Esophagitis, Peptic / diagnosis
  • Esophagitis, Peptic / drug therapy*
  • Female
  • Follow-Up Studies
  • Heartburn / drug therapy
  • Heartburn / epidemiology
  • Heartburn / etiology
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Proton-Translocating ATPases / antagonists & inhibitors
  • Rabeprazole
  • Time Factors
  • Treatment Outcome
  • United States / epidemiology

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Enzyme Inhibitors
  • Rabeprazole
  • Proton-Translocating ATPases